Swiss Market Closes Modestly Higher

RTTNews | 586 hari yang lalu
Swiss Market Closes Modestly Higher

(RTTNews) - The Switzerland stock market ended modestly higher on Tuesday after holding in positive territory right through the day's session.

Bargain hunting at several counter contributed to market's rebound.

The benchmark SMI, which rose to 10,201.23 in the first hour, ended the day with a gain of 53.81 points or 0.53% at 10,126.43.

Roche Holding rallied 2.2%. Logitech gained 2.05%, while Lonza Group, Zurich Insurance Group and ABB advanced 1 to 1.1%.

Novartis, Sika, Sonova and Swisscom posted modest gains.

Credit Suisse and Swiss Re both shed more than 2%. Swiss Life Holding ended lower by about 1.05%. Geberit and Alcon also ended weak.

Among the stocks in the Swiss Mid Price Index, Zur Rose surged 5.57%. AMS gained a little over 5%, and Roche Holding climbed 3.7%.

Galenica Sante, Kuehne & Nagel, Bachem Holding, Schindler Ps and Lindt & Spruengli gained 1.5 to 2.3%.

SGS, Swiss Prime Site, Clariant and PSP Swiss Property declined 2.4 to 2.9%.

read more
Eurozone Private Sector Growth Accelerates In April

Eurozone Private Sector Growth Accelerates In April

The euro area private sector growth accelerated to an 11-month high in April driven by the service sector, final survey results from S&P Global showed on Monday. The HCOB composite output index rose to 51.7 in April from 50.3 in the previous month. The flash estimate was 51.4.
RTTNews | 4h 0menit yang lalu
TC BioPharm Inks LOI To Acquire Privately-held CAR-T Therapy Innovator

TC BioPharm Inks LOI To Acquire Privately-held CAR-T Therapy Innovator

Biotechnology company TC BioPharm (Holdings) plc (TCBP) announced Monday the execution of a non-binding letter of intent to acquire a privately-held biotechnology company pursuing the development of innovative Chimeric Antigen Receptor T-cell (CAR-T) therapies for the treatment of refractory cancers and solid tumors.
RTTNews | 4h 21menit yang lalu
Bristol Myers Says Type II Variation Application For Opdivo + Yervoy Granted EMA Validation

Bristol Myers Says Type II Variation Application For Opdivo + Yervoy Granted EMA Validation

Bristol Myers Squibb Co. (BMY) announced Monday that the European Medicines Agency (EMA) has validated its Type II variation application for Opdivo (nivolumab) plus Yervoy (ipilimumab) for the first-line treatment of adult patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC).
RTTNews | 5h 1menit yang lalu
Bay Street Likely To Open On Firm Note

Bay Street Likely To Open On Firm Note

Higher Canadian and U.S. futures, and rising crude oil and bullion prices point to a positive start on Bay Street Monday morning. Optimism about rate cuts by the Fed and several central banks in Europe is also expected to aid market's rise.
RTTNews | 5h 5menit yang lalu
BioNTech Slips To Loss In Q1

BioNTech Slips To Loss In Q1

Immunotherapy company Biopharmaceutical New Technologies or BioNTech SE (BNTX) reported Monday a net loss of 315.1 million euros or 1.31 euros per share for the first quarter, compared to net profit of 502.2 million euros or 2.05 euros per share in the prior-year quarter.
RTTNews | 6h 7menit yang lalu
Eurozone Sentix Investor Confidence Rises For 7 Straight Months

Eurozone Sentix Investor Confidence Rises For 7 Straight Months

Eurozone investor confidence improved for the seventh straight month in May to hit the highest level since February 2022 as both current situation and expectations rose in small but steady steps, a closely watched survey showed on Monday. The investor confidence index posted -3.6 in May, the behavioral research institute Sentix reported. The score was forecast to improve moderately to -4.8.
RTTNews | 6h 16menit yang lalu